paper
discuss
techniqu
current
implement
vaccin
product
base
viruslik
particl
vlp
factor
determin
characterist
vlp
monom
assembl
provid
detail
analysi
literatur
demonstr
develop
techniqu
vlp
product
immobil
target
antigen
surfac
led
develop
univers
platform
make
possibl
virtual
known
antigen
expos
particl
surfac
highli
concentr
form
result
focu
attent
shift
approach
vlp
product
develop
precis
interfac
organ
immun
system
peptid
induc
strong
immun
respons
pathogen
organ
patholog
cell
immunomespecifi
method
vaccin
design
prospect
immunoprophylaxi
discuss
certain
exampl
vaccin
viral
diseas
cancer
consid
immunoprophylaxi
long
use
control
infecti
diseas
exert
enorm
impact
global
health
also
safeti
numer
popul
agricultur
anim
past
decad
focu
vaccin
product
technolog
chang
handl
intact
pathogen
produc
recombin
subunit
vaccin
base
isol
target
antigen
intens
develop
recombin
vaccin
began
becam
possibl
clone
desir
dna
sequenc
express
plasmid
produc
target
protein
construct
recombin
vaccin
take
advantag
knowledg
nucleotid
sequenc
gene
encod
pathogen
involv
identif
antigen
determin
synthesi
nucleotid
sequenc
encod
antigen
clone
express
vector
product
target
peptid
certain
express
system
express
system
individu
heterolog
protein
develop
base
prokaryot
eukaryot
cell
allow
us
produc
target
protein
laboratori
industri
scale
interest
recombin
vaccin
consequ
emerg
new
infecti
diseas
often
zoonot
one
among
outbreak
human
diseas
caus
ebola
viru
zika
viru
marburg
viru
middl
east
respiratori
syndrom
sever
acut
respiratori
syndrom
coronavirus
oncolog
also
place
great
hope
recombin
vaccin
may
help
overcom
immun
toler
case
cancer
treatment
moreov
exist
constant
threat
emerg
new
highli
virul
strain
wellknown
virus
due
unceas
mutat
process
viru
genom
background
new
scientif
concept
vaccinom
consist
identifi
minimum
subset
antigen
abl
induc
compet
immun
respons
pathogen
tumor
specif
interact
b
immun
cell
activ
develop
use
approach
appear
possibl
design
vaccin
base
minimum
subset
antigen
specif
character
pathogen
interact
immunom
set
immun
receptor
sequenc
present
individu
organ
target
detect
epitop
region
locat
surfac
protein
possibl
aid
xray
analysi
rather
laborconsum
sinc
requir
obtain
protein
crystal
present
protein
structur
model
found
broad
use
approach
base
identif
physicochem
electrostat
characterist
polypeptid
chain
region
correl
characterist
antigen
properti
two
strategi
current
util
name
model
homolog
abbrevi
vlp
viruslik
particl
udc
de
novo
model
first
case
protein
data
bank
http
wwwncbinlmnihqovgenbank
databas
protein
structur
use
model
protein
commonli
use
model
well
softwar
itass
swissmodel
phyre
cphmodel
use
homolog
model
tool
limit
approach
lie
requir
structur
homolog
protein
demonstr
ident
de
novo
model
strategi
base
comput
simul
protein
fold
process
rosetta
tasser
softwar
case
possibl
variant
polypeptid
chain
fold
consid
energet
favor
conform
ie
one
lowest
potenti
energi
chosen
predict
antigen
determin
synthes
use
genet
engin
vector
techniqu
heterolog
protein
express
system
experiment
test
use
exampl
antibodi
neutral
assay
use
protein
express
system
possibl
produc
viruslik
particl
vlp
made
monom
abl
multimer
vlp
display
antigen
determin
target
pathogen
surfac
point
address
review
observ
even
complex
epitop
repres
trimer
may
obtain
use
heterolog
express
system
demonstr
instanc
trimer
human
immunodefici
viru
envelop
glycoprotein
influenza
viru
haemagglutinin
order
choos
specif
antigen
patholog
agent
new
infecti
diseas
appear
inevit
work
infect
materi
isol
sequenc
nucleic
acid
contain
genet
inform
pathogen
howev
order
produc
vaccin
base
epitop
characterist
target
pathogen
need
work
pathogen
therefor
apart
advantag
vaccin
kind
appear
improv
term
biolog
safeti
vaccin
base
present
subset
antigen
determin
infecti
agent
character
high
level
reproduc
commerci
manufactur
highli
effect
sinc
case
immun
respons
direct
exclus
signific
antigen
element
pathogen
microorgan
tumor
number
vaccin
specif
interact
certain
immun
system
receptor
test
date
exampl
vaccin
contain
singl
epsteinbarr
viru
epitop
specif
recogn
tcell
propos
prophylaxi
mononucleosi
human
vaccin
prevent
develop
diseas
although
protect
organ
entri
viru
anoth
exampl
classic
swine
fever
viru
csfv
demonstr
viral
protein
produc
baculoviru
express
system
induc
synthesi
csfvneutral
antibodi
pig
vaccin
design
produc
immun
diseas
although
singl
epitop
abl
induc
strong
immun
respons
appear
usual
insuffici
induc
protect
immun
vitro
synthes
peptid
properli
repres
main
antigen
determin
pathogen
highli
like
strong
immunogen
primarili
small
size
nm
high
risk
proteolyt
degrad
problem
may
overcom
use
nanoparticl
shown
consider
number
work
order
induc
strong
immun
respons
antigen
determin
expos
surfac
nanoparticl
whose
shape
size
nm
mimic
viru
fig
respect
also
vlp
nanoparticl
compos
viral
protein
capabl
selfassembl
multimer
structur
morpholog
resembl
virus
choic
select
role
strong
immunogen
antigen
determin
multipli
repeatedli
vlp
surfac
promot
complement
fixat
blymphocyt
receptor
cluster
lead
activ
immun
respons
addit
antigen
multipli
display
surfac
particl
promot
multipl
pool
autoreact
bcell
primari
object
design
vaccin
autoimmun
diseas
tumor
natur
sourc
vlp
bioengin
specif
featur
assembl
structur
protein
variou
virus
capabl
autonom
selfassembl
vlp
interact
format
globular
icosahedr
rodlik
structur
far
structur
protein
sever
dozen
virus
obtain
heterolog
express
system
almost
prove
abl
form
vlp
vlp
size
vari
nm
similar
size
correspond
virus
similar
virus
allow
vlp
penetr
lymph
effici
entrap
antigenpres
cell
current
sever
heterolog
express
system
correspond
express
vector
use
avail
system
base
bacteri
cell
pet
system
base
escherichia
coli
cell
often
exploit
differ
eukaryot
cell
case
eukaryot
cell
commonli
use
system
yeast
express
system
one
reli
drosophila
spodoptera
frugiperda
insect
cell
line
mammalian
cell
also
util
popular
among
cho
cost
heterolog
protein
product
bacteri
system
lower
eukaryot
cell
howev
studi
function
activ
protein
vlp
associ
exampl
potenti
glycosyl
site
interact
ubiquitin
ubiquitinlik
peptid
altern
eukaryot
express
system
avail
note
choic
express
system
research
driven
research
task
exampl
differ
laboratori
differ
eukaryot
system
viral
protein
express
includ
plant
cell
use
produc
vlp
use
vaccin
hepat
c
viru
hcv
case
vlp
assembl
viru
protein
consid
candid
vaccin
viru
sinc
protein
monom
multimer
configur
vlp
induc
potent
immun
respons
protein
monom
strong
immunogen
properti
vlp
determin
sever
factor
first
domin
epitop
structur
protein
display
part
particl
present
multimer
form
case
nativ
virion
second
vlp
stimul
blymphocyt
induc
tlymphocyt
manner
viru
infect
host
organ
exampl
vlp
form
main
capsid
protein
human
papilloma
viru
sever
serotyp
success
use
vaccin
cervic
cancer
vaccin
hepat
b
viru
produc
contain
vlp
lipid
membran
envelop
vaccin
coxsackieviru
contain
vlp
assembl
viru
capsid
protein
produc
baculoviru
express
system
scientist
china
demonstr
capsid
protein
rabbit
hemorrhag
diseas
viru
rhdv
effici
multimer
vlp
singl
intramuscular
inject
obtain
vlp
prepar
complet
protect
immun
rabbit
rhdv
infect
least
day
porcin
circoviru
capsid
protein
also
abl
effici
assembl
vlp
synthes
either
human
embryon
kidney
cell
cultur
yeast
baculoviru
express
system
well
bacteria
footandmouth
diseas
vlp
assembl
three
structur
polypeptid
natur
produc
result
process
precursor
polypeptid
simultan
produc
e
coli
recent
demonstr
polyprotein
liposomebas
particl
nondegrad
spheric
nanoparticl
exampl
metal
nanoparticl
polym
nanoparticl
graphen
nanosheet
nanotub
antigen
duck
hepat
viru
produc
baculoviru
express
system
assembl
vlp
immedi
cultur
spodoptera
frugiperda
cell
immun
duckl
obtain
vlp
induc
high
level
humor
immun
respons
protect
develop
diseas
abil
vlp
result
multimer
clone
viru
protein
play
role
immunogen
limit
present
proper
epitop
may
also
taken
advantag
display
heterolog
protein
multimer
capsid
protein
particl
requir
presenc
nucleic
acid
vitro
assembl
short
oligonucleotid
nt
suffici
therefor
vpl
form
capsid
protein
free
infecti
viru
rna
dna
moreov
abovement
properti
trigger
protein
monom
multimer
nucleic
acid
may
taken
advantag
packag
rna
dna
particl
two
differ
object
henc
antisens
rna
use
suppress
viru
express
exampl
case
vaccin
footandmouth
diseas
research
china
display
epitop
footandmouth
diseas
viru
surfac
vlp
also
packag
antisens
rna
complementari
fragment
viral
genom
rna
particl
anoth
goal
nucleic
acid
packag
particl
lie
present
viral
nucleic
acid
lead
activ
specif
immun
receptor
induc
synthesi
type
interferon
inf
cytokin
trigger
antiviru
respons
demonstr
long
dna
rna
molecul
may
incorpor
vlp
exampl
mrna
report
protein
red
fluoresc
protein
packag
particl
repres
hepat
e
capsid
plasmid
contain
green
fluoresc
protein
gfp
gene
encapsid
vlp
assembl
vitro
main
capsid
protein
hamster
polyoma
viru
strategi
packag
kbp
doublestrand
circular
dna
particl
develop
use
structur
protein
simian
retroviru
express
baculoviru
system
exist
two
fundament
differ
approach
nucleic
acid
incorpor
vlp
vitro
vlp
assembl
protein
monom
presenc
rna
dna
encapsid
vlp
exposur
assembl
vlp
osmot
shock
presenc
nucleic
acid
osmot
shock
produc
use
solut
low
ionic
strength
nucleic
acid
enter
vlp
result
shift
surfac
structur
howev
incub
vlp
presenc
nucleic
acid
without
exposur
osmot
stress
result
certain
part
nucleic
acid
becom
associ
particl
far
predict
approach
vitro
assembl
vlp
mixtur
protein
monom
nucleic
acid
encapsid
case
synthesi
heterolog
system
obtain
protein
monom
purifi
complet
remov
contamin
nucleic
acid
protein
prepar
protein
denatur
urea
nucleic
acid
packag
ad
protein
assembl
particl
elimin
urea
solut
use
strategi
demonstr
instanc
work
protein
associ
particl
revers
process
vlp
dissoci
easili
achiev
addit
denatur
agent
may
remov
vlp
may
reassembl
vitro
encapsid
target
rna
dna
particl
approach
implement
protein
hepat
b
viru
viru
protein
produc
heterolog
express
system
denatur
urea
solut
assembl
vlp
presenc
nucleic
acid
induc
protect
immun
control
specif
humor
cellular
mechan
activ
antigen
posttransl
protein
modif
coval
bond
modifi
molecul
function
group
polypeptid
chain
great
import
immun
homeostasi
antivir
respons
balanc
phosphoryl
ubiquitin
methyl
acetyl
sumoyl
adpribosyl
glutamil
certain
antigen
perform
fine
adjust
host
antivir
respons
structur
protein
vlp
product
synthes
eukaryot
express
system
undergo
number
posttransl
modif
particular
gag
gypsi
monom
prove
natur
substrat
type
casein
kinas
moreov
produc
eukaryot
cell
gag
gypsi
monom
becom
associ
ubiquitin
sumo
cellular
protein
partner
viral
structur
protein
gener
ubiquitin
sumo
bind
lysin
residu
within
protein
molecul
although
prefer
bind
site
also
note
phosphoryl
determin
two
partner
bind
protein
addit
bind
limit
number
abovement
signal
peptid
monoubiquitin
usual
play
regulatori
role
control
transport
protein
particl
form
case
polyubiquitin
protein
destin
proteasom
degrad
construct
recombin
polypeptid
base
viral
capsid
protein
possibl
obtain
vlp
bear
sever
antigen
exampl
dna
encod
capsid
protein
porcin
parvoviru
fuse
dna
fragment
encod
amino
acid
residu
main
antigen
porcin
circoviru
nucleoprotein
result
hybrid
dna
use
produc
protein
heterolog
cell
form
vlp
vlp
induc
significantli
stronger
immun
respons
recombin
adenoviru
encod
open
read
frame
anoth
interest
exampl
repres
vlp
form
influenza
viru
matrix
protein
display
toxoplasma
gondii
antigen
surfac
exist
anoth
approach
design
therapeut
vaccin
base
vlp
case
vlp
surfac
display
variabl
fragment
antibodi
specif
antigen
target
viru
moreov
know
receptor
bound
viru
protein
render
possibl
produc
particl
possess
tropism
cell
certain
tissu
exampl
presprotein
hepat
b
viru
expos
ligand
vlp
surfac
provid
specif
bind
hepatocyt
vlp
assembl
structur
protein
bacteriophag
also
consid
carrier
human
anim
vaccin
product
exampl
dna
fragment
encod
foreign
protein
insert
dna
region
encod
ntermin
coat
protein
e
coli
phage
demonstr
express
obtain
construct
bacteri
cell
result
product
recombin
protein
foreign
peptid
present
central
part
hairpin
obtain
chimer
protein
monom
abl
selfassembl
particl
morpholog
similar
phage
capsid
vivo
vitro
use
mention
properti
coat
protein
vlp
display
epitop
footandmouth
diseas
structur
protein
surfac
obtain
chimer
vlp
induc
string
immun
respons
anim
allow
regard
promis
base
develop
prophylact
vaccin
worth
note
exposur
vlp
surfac
resolv
longstand
problem
make
use
benefici
properti
peptid
research
sever
laboratori
demonstr
antigen
determin
footandmouth
diseas
induc
product
neutral
antibodi
also
stimul
tlymphocyt
howev
isol
abl
induc
immun
respons
protect
anim
footandmouth
viru
infect
mani
attempt
made
solv
problem
exampl
combin
antigen
determin
larg
molecul
instanc
cellspecif
molecul
howev
integr
vlp
result
possibl
use
antigen
determin
strong
immunogen
vaccin
product
practic
structur
protein
phage
infect
variou
speci
bacteria
abl
autonom
form
vlp
exampl
salmonella
typhimurium
phage
abl
autonom
multimer
vlp
whose
surfac
epitop
eukaryot
virus
includ
epitop
human
influenza
viru
may
expos
time
howev
bacteriophag
appar
incap
present
larg
epitop
whose
length
exce
amino
acid
residu
structur
protein
retrovirus
retrotransposon
higher
capac
compar
bacteriophag
protein
mean
protein
monom
form
particl
may
fuse
longer
peptid
still
retain
abil
multimer
particular
shown
gag
gypsi
capsid
protein
least
amino
acid
sequenc
amino
acid
residu
littl
import
multimer
vlp
therefor
truncat
form
protein
may
fuse
heterolog
peptid
length
similar
length
delet
fragment
recombin
protein
may
obtain
retain
abil
selfassembl
vlp
way
truncat
gag
gypsi
fuse
heterolog
peptid
form
particl
synthes
bacteri
cell
also
abl
assembl
particl
purifi
protein
monom
vitro
obtain
particl
resembl
nativ
gypsi
viru
morpholog
substitut
delet
region
dna
encod
gag
gypsi
nucleotid
sequenc
encod
main
antigen
determin
footandmouth
viru
protein
tag
result
format
particl
display
target
antigen
advantag
techniqu
use
vlp
form
protein
contain
tag
readili
isol
purifi
affin
chromatographi
chimer
vlp
may
obtain
construct
recombin
dna
molecul
encod
correspond
viru
protein
foreign
peptid
protein
anoth
way
vlp
pseudotyp
approach
elabor
use
hamster
polyomaviru
capsid
protein
viru
first
form
pentam
assembl
vlp
compris
pentam
express
togeth
minor
capsid
protein
latter
bind
central
part
pentam
demonstr
ntermin
part
involv
interact
therefor
may
remov
substitut
target
epitop
anoth
approach
also
known
antigen
immobil
vlp
via
coval
bind
reactiv
group
amino
acid
residu
antigen
vlp
approach
prove
ineffect
due
disrupt
nativ
conform
antigen
attach
particl
surfac
problem
counter
follow
way
glyglylysglygli
sequenc
insert
monom
subunit
vlp
assembl
environ
reactiv
group
ly
residu
expos
readi
interact
cysgroup
protein
presenc
crosslink
agent
mmaleimidobenzoylnhydroxysulfosuccinimid
ester
sulfomb
hexano
smph
although
author
claim
describ
system
molecular
assembl
may
use
induc
strong
blymphocyt
respons
antigen
prospect
vaccin
prototyp
suggest
platform
becam
prototyp
singl
prospect
prepar
base
vlp
medic
lower
blood
pressur
patient
hypertens
due
develop
new
improv
techniqu
antigen
immobil
vlp
surfac
discuss
one
take
advantag
abil
bind
multival
trisnitrilotriacet
acid
trisnta
turn
bind
broad
rang
molecul
particular
biotin
possibl
eleg
techniqu
function
noninfecti
viral
nanoparticl
demonstr
case
vlp
form
noroviru
nov
structur
protein
use
baculoviru
express
system
author
obtain
nov
vlp
display
tag
surfac
first
use
purifi
vlp
bind
trisnta
molecul
conjug
fluoresc
dye
biotin
turn
success
bound
streptavidin
notwithstand
author
suggest
describ
techniqu
promis
vlp
vaccin
product
approach
continu
prototyp
advanc
model
experi
search
techniqu
provid
effici
stabl
immobil
antigen
vlp
surfac
led
develop
versatil
platform
allow
us
coval
attach
larg
antigen
vlp
surfac
molecular
assembl
system
use
tagcatch
conjug
system
deriv
domain
fibronectinbind
protein
fbab
streptococcu
pyogen
result
highli
reactiv
spytag
peptid
amino
acid
residu
obtain
effici
interact
spycatch
protein
format
isopeptid
bond
broad
rang
buffer
solut
spytag
peptid
insert
vlpform
polypeptid
acinetobacterinfect
phage
particl
call
monom
form
display
two
spytag
peptid
recombin
antigen
consist
target
protein
spycatch
peptid
produc
use
bacteri
baculoviru
express
system
obtain
antigen
effici
bound
vlp
surfac
induc
strong
immun
respons
almost
effect
observ
case
revers
combin
conjug
peptid
spycatch
incorpor
vlp
spytag
fuse
antigen
system
alreadi
util
design
differ
type
vaccin
includ
vaccin
tuberculosi
malaria
recent
report
demonstr
success
use
develop
vaccin
breast
cancer
work
remark
due
fact
high
densiti
antigen
human
epiderm
factor
receptor
synthes
cultur
drosophila
melanogast
cell
could
obtain
vlp
surfac
obtain
particl
induc
strong
immun
respons
antigen
patient
render
possibl
overcom
immun
toler
known
patient
breast
cancer
summari
analysi
discuss
publish
data
allow
us
conclud
natur
vlpform
protein
import
vlp
function
techniqu
make
possibl
obtain
high
antigen
densiti
surfac
vlp
tabl
product
rang
number
vlp
vaccin
avail
pharmaceut
market
mani
countri
wellknown
vaccin
cervic
cancer
success
use
prophylaxi
diseas
girl
ten
year
vaccin
base
vlp
form
main
capsid
protein
human
papilloma
viru
belong
sever
serotyp
engerix
recombivax
hb
vaccin
hepat
b
viru
repres
vlp
envelop
lipid
membran
well
hecolin
xiamen
innovax
vaccin
hepat
e
develop
commerci
antimalaria
vaccin
malaria
rt
certifi
repres
ctermin
part
cs
protein
plasmodium
falciparum
attach
surfac
antigen
hepat
b
viru
hbsag
also
use
certifi
vaccin
hepat
b
stabil
recombin
vlp
fuse
protein
express
togeth
hbsag
protein
saccharomyc
cereviseas
vaccin
porcin
circoviru
repres
vlp
assembl
capsid
protein
synthes
heterolog
system
also
commerci
increas
number
work
appear
report
develop
vaccin
base
nanoparticl
includ
vlp
andor
replicationinact
virus
among
appar
advantag
vaccin
kind
high
specif
effici
good
pharmacokinet
characterist
demonstr
organ
vlp
reach
lymphat
node
less
min
particl
mixtur
bear
differ
antigen
may
process
antigenpres
cell
simultan
note
nanoprticlebas
vaccin
offer
new
possibl
develop
immunoprophylaxi
strategi
especi
develop
injectionfre
formul
particular
intranas
vaccin
inhal
administr
vaccin
may
involv
human
especi
import
case
industri
anim
breed
larg
agricultur
enterpris
characterist
presentday
russia
sinc
prove
extrem
difficult
administ
ident
inject
larg
number
anim
time
problem
may
resolv
nebul
aerosol
vaccin
area
anim
kept
potenti
approach
demonstr
first
time
mice
attempt
made
introduc
approach
anim
poultri
farm
mani
countri
start
attempt
also
made
soviet
union
howev
time
method
inhal
administr
vaccin
introduc
practic
sinc
protect
immun
could
obtain
toler
dose
exceed
mani
time
exampl
inhal
administr
vaccin
newcastl
diseas
led
lethal
bird
howev
due
introduct
vaccin
base
exposur
epitop
pathogen
surfac
nanoparticl
includ
recombin
vlp
togeth
develop
innov
approach
aerosol
product
inhal
vaccin
becam
topic
issu
exampl
biodegrad
polym
nanoparticl
form
poli
pgacopdl
prove
effect
antigen
carrier
inhal
vaccin
vaccin
base
adenoviru
particl
rang
induc
stabl
protect
immun
administ
via
inhal
monkey
lastli
method
vlpvaccin
via
inhal
propos
protect
human
papilloma
viru
one
import
properti
vlp
mimick
viru
particl
consequ
abil
induc
strong
immun
respons
antigen
demonstr
irrespect
sourc
monom
multimer
vlp
either
insect
virus
particular
gypsi
viru
plant
virus
vlp
base
structur
protein
plant
virus
produc
plant
make
possibl
obtain
vaccin
anoth
nonconvent
way
administr
edibl
vaccin
vaccin
type
may
synthes
directli
plant
forag
oral
vaccin
kind
induc
immun
respons
express
vector
foreign
protein
product
plant
develop
base
plant
virus
allow
obtain
plantproduc
recombin
virus
vlp
display
target
antigen
surfac
vlp
assembl
structur
protein
plant
virus
also
use
design
function
platform
antigen
bind
platform
base
strategi
describ
particular
take
advantag
reactiv
ly
immobil
antigen
surfac
plant
vlp
use
tobacco
mosaic
viru
potato
x
viru
shown
consider
larg
antigen
immobil
surfac
correspond
vlp
via
format
streptavidinbiotin
complex
final
base
structur
protein
plant
viru
platform
antigen
immobil
use
tagcatch
conjug
system
develop
note
among
drawback
vlp
vaccin
manufactur
use
protein
specif
mammal
exampl
plant
viru
protein
includ
develop
immun
respons
structur
compon
particl
plant
viru
protein
undoubtedli
therapeut
benefit
develop
immun
howev
whether
advers
effect
demonstr
studi
model
molecul
includ
biotin
alexa
fluoresc
dye
gfp
protein
conjug
trisnta
isopeptid
bond
format
spytag
integr
vlp
monom
spycatch
fuse
antigen
peptid
vaccin
breast
cancer
antigen
present
also
implement
develop
vaccin
malaria
tuberculosi
use
vlp
vaccin
medicin
becom
increasingli
widespread
point
reinforc
list
clinic
trial
vlp
vaccin
prepar
unit
state
nation
institut
health
current
hundr
vlp
vaccin
direct
human
avian
influenza
virus
norwalk
viru
noroviru
chikungunya
viru
footandmouth
diseas
viru
well
melanoma
adenocarcinoma
papillomatos
cervic
cancer
undergo
clinic
trial
http
may
expect
varieti
nanoparticl
vaccin
differ
cancer
viral
infect
grow
steadili
vlp
use
immun
microorgan
belong
differ
taxon
well
helminth
also
develop
thank
design
oleg
vasilev
galina
podzolkova
institut
statist
studi
econom
knowledg
issek
nation
research
univers
higher
school
econom
assist
prepar
illustr
articl
prepar
within
framework
basic
research
program
nation
research
univers
higher
school
econom
hse
support
within
framework
subsidi
russian
academ
excel
project
author
declar
conflict
interest
articl
contain
studi
involv
anim
human
particip
perform
author
